Navigation Links
Oxygen Biotherapeutics, Inc. to Present at Investment Conferences in New York and Zurich
Date:8/26/2009

DURHAM, N.C., Aug. 26 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that the company will present at investor conferences in New York on Sept. 9 and Zurich on Sept. 10, 2009.

Kirk Harrington, senior vice president, Warfighter Division and Government Affairs, will present at the Rodman & Renshaw Annual Global Investment Conference in New York on September 9, 2009 at 2:00 p.m. eastern time.

A live, audio webcast of Harrington's presentation will be available through the Investor Relations section of the Oxygen Biotherapeutics, Inc. website. A replay will be available following the event. Webcast login information will be provided on the company website prior to the presentation.

The following day, the company chairman and CEO, Chris Stern, will present at an investor conference in Zurich. The presentation will be at the Dolder Grand Hotel and is scheduled for 5:00 p.m. in the Garden Salon. The Zurich presentation will not be webcast but will be open to interested investors.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has under development a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications. More information is available at www.oxybiomed.com.


'/>"/>
SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009
2. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
3. Brain Monitor Eliminates Need for Routine Oxygen With Propofol - Friedberg's Triad Unveiled
4. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
5. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
6. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
7. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
8. Oxygen Biotherapeutics, Inc. Expands Board of Directors
9. Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment
10. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
11. Finesse Introduces TruFluor(TM) DO, a Single-Use Optical Dissolved Oxygen Sensor and Transmitter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... 09, 2016 , ... The publishing industry has been witnessing ... one of the popular publication models that has received wider acknowledgement from the ... International Conferences across the globe, OMICS International is all set to ...
(Date:2/9/2016)... HOUSTON , Feb. 9, 2016 /PRNewswire/ ... virus-driven immunotherapies for cancer, announced that its ... the European Commission as an orphan medicinal ... the deadliest form of glioma, strikes approximately ... and EU. http://photos.prnewswire.com/prnh/20160208/330986LOGO ...
(Date:2/9/2016)... and LONDON , February 9, 2016 ... bio tech replace paper and protect IP ... electronic laboratory notebook (ELN) will be rolled out in ... research and development (R&D) and protect valuable IP. Users will ... follow a specific researcher or experiment as part of the ...
(Date:2/9/2016)... 9, 2016 BERG, a biopharmaceutical company ... approach, has announced the appointment of Jason ... Operating Officer. Haddock brings to BERG over 20 ... years in senior financial functions at pharmaceutical companies, ... organizational management. Niven R. Narain ...
Breaking Biology Technology:
(Date:1/22/2016)... , January 22, 2016 /PRNewswire/ ... announced the addition of the  "Global ... their offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ...
(Date:1/20/2016)... 2016  Synaptics Incorporated (NASDAQ: SYNA ), ... announced sampling of S1423, its newest ClearPad ® ... screen applications including smartwatches, fitness trackers, and touch ... rectangular shapes, as well as thick and curved ... on screen, while wearing gloves, and supports swipes ...
(Date:1/11/2016)... 2016 Synaptics Incorporated (NASDAQ: SYNA ), ... that its ClearPad ® TouchView ™ 4300 ... separate categories in the 8 th Annual Mobile ... Breakthrough. The Synaptics ® TDDI solution enables faster ... thinner devices, brighter displays and borderless designs. ...
Breaking Biology News(10 mins):